GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BG Medicine Inc (OTCPK:BGMD) » Definitions » Debt-to-EBITDA

BG Medicine (BG Medicine) Debt-to-EBITDA : 0.00 (As of Dec. 2015)


View and export this data going back to 2011. Start your Free Trial

What is BG Medicine Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BG Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2015 was $0.00 Mil. BG Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2015 was $0.00 Mil. BG Medicine's annualized EBITDA for the quarter that ended in Dec. 2015 was $-3.54 Mil. BG Medicine's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2015 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BG Medicine's Debt-to-EBITDA or its related term are showing as below:

BGMD's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.21
* Ranked among companies with meaningful Debt-to-EBITDA only.

BG Medicine Debt-to-EBITDA Historical Data

The historical data trend for BG Medicine's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BG Medicine Debt-to-EBITDA Chart

BG Medicine Annual Data
Trend Dec05 Dec06 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.44 -0.50 -0.41 -

BG Medicine Quarterly Data
Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 -0.38 -0.22 - -

Competitive Comparison of BG Medicine's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, BG Medicine's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BG Medicine's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BG Medicine's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BG Medicine's Debt-to-EBITDA falls into.



BG Medicine Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BG Medicine's Debt-to-EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -5.057
=0.00

BG Medicine's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2015 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -3.536
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2015) EBITDA data.


BG Medicine  (OTCPK:BGMD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BG Medicine Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BG Medicine's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BG Medicine (BG Medicine) Business Description

Traded in Other Exchanges
N/A
Address
303 Wyman Street, Suite 300, Waltham, MA, USA, 02451
BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Executives
Jeffrey R Luber director 100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Stelios Papadopoulos director 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Harry W Wilcox director ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139
Agtc Partners, L.p. 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Newcogen Group, Inc. 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Applied Genomic Technology Capital Fund Lp 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Flagship Pioneering Inc. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Agtc Advisors Fund Lp 10 percent owner ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142
Kania Edwin M Jr 10 percent owner
Flagship Ventures Fund 2007, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures 2007 General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Stephane Bancel director 320 BENT STREET, CAMBRIDGE MA 02141
Harris Timothy J.r. director C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451

BG Medicine (BG Medicine) Headlines

No Headlines